Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 08/08/20031 min de lecture
Agency Information Collection Activities; Announcement of OMB Approval; Applications for FDA Approval to Market a New Drug: Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be Infringed
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Applications for FDA Approval to Market a New Drug: Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be Infringed" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →